Get the Stockscreener App
1.70
2.30%
-0.04
After Hours:
1.69
-0.01
-0.59%
Inflarx Nv stock is traded at $1.70, with a volume of 928.39K.
It is down -2.30% in the last 24 hours and down -11.46% over the past month.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$1.74
Open:
$1.75
24h Volume:
928.39K
Relative Volume:
0.50
Market Cap:
$250.40M
Revenue:
$72,500
Net Income/Loss:
$-45.96M
P/E Ratio:
-2.4949
EPS:
-0.6814
Net Cash Flow:
$-44.56M
1W Performance:
-6.59%
1M Performance:
-11.46%
6M Performance:
+75.86%
1Y Performance:
+89.16%
1-Day Range:
$1.68
$1.80
1-Week Range:
$1.68
$1.865
52-Week Range:
$0.7406
$2.9489
Inflarx Nv Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx Nv
|
1.70 | 256.29M | 72,500 | -45.96M | -44.56M | -0.6814 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Inflarx Nv Stock (IFRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-02-25 | Resumed | H.C. Wainwright | Buy |
| May-29-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-06-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-20 | Initiated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Apr-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-05-19 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-05-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-05-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Jun-05-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| Dec-10-18 | Initiated | Credit Suisse | Outperform |
| Jul-13-18 | Initiated | BMO Capital Markets | Outperform |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-28-18 | Initiated | SunTrust | Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Inflarx Nv Stock (IFRX) Latest News
InflaRx NV (IFRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InflaRx NV (IFRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InflaRx NV (IFRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InflaRx N.V. Revenue Breakdown – SWB:IF0 - TradingView
IFRX|InflaRx NV|Price:1.740|Chg%:+0.010 - TradingKey
TradingKey - TradingKey
InflaRx N.V. Revenue Breakdown – BOATS:IFRX - TradingView
InflaRx NV (IFRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
InflaRx (IFRX) Under Pressure as Shares Slip 2.88% Toward Key SupportAlgorithmic Stock Picks - dars.gov.et
IFRX Stock Price, Quote & Chart - ChartMill
IFRX Q1 2026 Earnings: Narrower-than-Expected Loss on Stability, Stock EasesEarnings Call Q&A - DonanımHaber
InflaRx NV focus on immune therapies as investors weigh long-term prospects - ad-hoc-news.de
InflaRx N.V. (IFRX) Slips 1.79% as Stock Approaches Key Support LevelETF Premium Discount - DonanımHaber
IFRX Q1 2026 Earnings: Surprise EPS Beat Despite Pre-Revenue StatusCapex Guidance - dars.gov.et
Price to earnings forward of InflaRx N.V. – NASDAQ:IFRX - TradingView
IFRXInflaRx NV Revenue Breakdown - Finviz
Price to book forward of InflaRx N.V. – NASDAQ:IFRX - TradingView
InflaRx Moves to Broaden AAV Strategy in Europe After EMA Setback for Tavneos - TipRanks
InflaRx (IFRX) rethinks European AAV path after EMA Tavneos setback - Stock Titan
InflaRx to explore regulatory path for AAV drugs in Europe - Investing.com
InflaRx to explore regulatory path for AAV drugs in Europe By Investing.com - Investing.com South Africa
InflaRx to Engage EMA on Vilobelimab and Izicopan Development Path in AAV - Quiver Quantitative
InflaRx Assessing Feasibility of Broadened Strategy - One News Page
symbol__ Stock Quote Price and Forecast - CNN
Price to sales forward of InflaRx N.V. – NASDAQ:IFRX - TradingView
Enterprise value to EBITDA forward of InflaRx N.V. – NASDAQ:IFRX - TradingView
Price to earnings forward of InflaRx N.V. – GETTEX:IF0 - TradingView
Price to sales forward of InflaRx N.V. – GETTEX:IF0 - TradingView
Price to book forward of InflaRx N.V. – GETTEX:IF0 - TradingView
Enterprise value to revenue forward of InflaRx N.V. – NASDAQ:IFRX - TradingView
Enterprise value to EBIT forward of InflaRx N.V. – GETTEX:IF0 - TradingView
ETFs Investing in InflaRx N.V. Stocks - TradingView
InflaRx N.V. Actuals & Estimates (HAM:IF0) - TradingView
InflaRx N.V. Actuals & Estimates (GETTEX:IF0) - TradingView
IFRX Forecast — Price Target — Prediction for 2027 - TradingView
InflaRx NV (IFRX) Institutional Confidence - TradingKey
InflaRx NV (IFRX) price target decreased by 16.67% to 7.29 - MSN
InflaRx NV (IFRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InflaRx N.V. (IFRX) Holds Near Support as Biotech Sentiment WeighsVolatility Breakout Picks - DonanımHaber
InflaRx NV (IFRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
InflaRx NV (IFRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InflaRx StockAnalyst views and trading setup midweek - AD HOC NEWS
InflaRx NV (IFRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
IFRX Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline, Though Stock DeclinesStrong Earnings Momentum - newsline.com
InflaRx N.V. Q1 2026 Earnings: Narrower-than-Expected Loss Despite Stock DeclineEarnings Growth Forecast - newsline.com
IFRX Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical Progress; Stock SlipsPost-Announcement Reaction - newsline.com
What Do Analysts Say About InflaRx N.V. (IFRX)? - Insider Monkey
InflaRx N.V. (IFRX) Q1 2026 Earnings: EPS Exceeds Expectations as Drug Development Advances - newsline.com
InflaRx N.V. (IFRX) Q4 2025 Earnings: Narrower-than-Expected Loss but Shares Slide 8%Buyback Announcement Report - dars.gov.et
IFRX Q4 2025 Earnings: Narrower-than-Expected Loss Fails to Stem Stock DeclinePre-Earnings Drift - newsline.com
Inflarx Nv Stock (IFRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):